Ipsen SA

Ipsen S.A. - Annual General Meeting held on 21 May 2025

21 May 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

12 May 2025 09:00:00 By Nasdaq GlobeNewswire

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis

06 May 2025 23:00:00 By Nasdaq GlobeNewswire

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

05 May 2025 22:30:00 By Nasdaq GlobeNewswire

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

30 Apr 2025 09:00:00 By Nasdaq GlobeNewswire

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

23 Apr 2025 23:14:23 By Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

15 Apr 2025 21:57:00 By Nasdaq GlobeNewswire

Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

14 Apr 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen publishes its 2024 Universal Registration Document

08 Apr 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen announces issuance of €500 million inaugural Rated Public Bond

18 Mar 2025 23:00:00 By Nasdaq GlobeNewswire

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

11 Mar 2025 23:28:00 By Nasdaq GlobeNewswire

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Mar 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2024 consolidated financial statements

21 Feb 2025 06:42:27 By Nasdaq GlobeNewswire

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

12 Feb 2025 21:57:00 By Nasdaq GlobeNewswire

Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Feb 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen - Half year statement - 2024 12 31

07 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Dec 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

02 Dec 2024 22:00:00 By Nasdaq GlobeNewswire

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15 Nov 2024 08:00:00 By Nasdaq GlobeNewswire